Ruvidar(TM) Enhances Efficacy of Cancer Drug

Theralase® Technologies Inc., a company specializing in the development of light and radiation activated molecules for cancer treatment, announced promising preclinical results. Their lead compound, Ruvidar™, when combined with Bacillus Calmette-Guérin (BCG), forms a new synergistic compound called RuBCG.

In tests, RuBCG significantly increased cancer cell kill rates compared to BCG or Ruvidar™ alone. This is due to the reversal of the cell wall charge of BCG, enhancing the attachment and effectiveness against bladder cancer cells.

BCG has been a standard treatment for Non-Muscle Invasive Bladder Cancer (NMIBC) but is only effective in 75% of patients, with 50% relapsing within a year. The new RuBCG formulation aims to address this limitation by increasing immunogenicity and cytotoxicity against cancer cells.